You just read:

Frost & Sullivan Publishes Q3-2018 Update Report on RedHill Biopharma Ltd.: RedHill published additional data from MAP US Phase III study of RHB-104 in Crohn's Disease; Steady-state sales in GI drugs; target price unchanged

News provided by

Frost & Sullivan

Nov 23, 2018, 10:01 ET